Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 15/20 | 0.79 |
| ▸ | CX3CR1 | P49238 | 11/20 | 0.70 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.69 |
| ▸ | PAK4 | O96013 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868599 | 0.89 | CXCR2 (1.00) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL842323 | 0.88 | CXCR2 (0.64) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6866465 | 0.87 | CXCR2 (0.62) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6864143 | 0.87 | CXCR2 (0.62) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL842868 | 0.85 | CXCR2 (0.63) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6864523 | 0.85 | PAK4 (0.72) | CXCR2CX3CR1PAK4 | |
| SCHEMBL6869027 | 0.85 | CXCR2 (0.61) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6866690 | 0.85 | CXCR2 (0.61) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6865690 | 0.85 | CXCR2 (0.60) | CXCR2CX3CR1CXCR1PAK4 | |
| SCHEMBL6863672 | 0.85 | PAK4 (0.62) | CXCR2CX3CR1CXCR1PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | claimed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-8143261-B2 | Thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED | 2009-11-12 | — | — | US | disclosed |
| EP-1348709-B1 | Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis | ASTRAZENECA UK LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-6958343-B2 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA, AB (SE) | 2005-10-25 | — | — | US | disclosed |
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | disclosed |
| US-6790850-B1 | Thiazolo(4,5-d)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2004-09-14 | — | — | US | disclosed |
| EP-1257556-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1222195-B1 | NOVEL THIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2004-01-14 | — | — | EP | disclosed |
| EP-1348709-A2 | Thiazolo (4,5-D) pyrimidine compounds | AstraZeneca UK Limited (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | US | disclosed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1104425-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009511-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | TYMS, DPYD, TYMP | CXCR2 378/4885CX3CR1 2551/4885CXCR1 318/4885 |
| US-20030032642-A1 | Thiazolopyrimidines and thier use as modulators of chemokine receptor activity | CCR5, CCR2, CXCR4 | CXCR2 5/4885CX3CR1 9/4885CXCR1 6/4885 |
| US-20090281123-A1 | NOVEL THIAZOLO (4,5-D) PYRIMIDINE COMPOUNDS NOVEL COMPOUNDS | TYMS, DPYD, TPMT | CXCR2 195/4885CX3CR1 2122/4885CXCR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.